Litigation Details for Harmony Biosciences, LLC v. MSN Pharmaceuticals Inc. (D. Del. 2023)

Harmony Biosciences, LLC v. MSN Pharmaceuticals Inc. (D. Del. 2023)

Docket		Date Filed	2023-12-11
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	8,207,197; 8,354,430; 8,486,947
Link to Docket	External link to docket

Details for Harmony Biosciences, LLC v. MSN Pharmaceuticals Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-12-11				External link to document

Harmony Biosciences, LLC v. MSN Pharmaceuticals Inc. Patent Litigation Analysis

Last updated: February 19, 2026

This document analyzes the patent litigation between Harmony Biosciences, LLC and MSN Pharmaceuticals Inc. concerning Harmony's narcolepsy treatment drug, Wakix (pitolisant). The core of the dispute centers on MSN's proposed generic version of Wakix and Harmony's assertion of patent infringement.

What Are the Key Patents in Dispute?

Harmony Biosciences asserts infringement of U.S. Patent No. 11,300,434 ("the '434 patent") and U.S. Patent No. 11,584,211 ("the '211 patent").

• '434 Patent: Titled "Preparation of 1-(2-ethoxybenzyl)-3-(2-furanyl)-2-pyrrolidinone for use in treating narcolepsy." This patent covers specific methods for synthesizing pitolisant, the active pharmaceutical ingredient in Wakix. It claims processes that yield pitolisant with high purity.
• '211 Patent: Titled "Method of treating narcolepsy with pitolisant." This patent claims methods of using pitolisant to treat narcolepsy.

What Are the Allegations in the Complaint?

Harmony Biosciences filed its complaint on September 12, 2023, alleging that MSN Pharmaceuticals' Abbreviated New Drug Application (ANDA) seeking approval for a generic version of Wakix infringes on its patents.

Harmony claims that MSN's proposed generic product will be manufactured using a process that infringes the '434 patent. Additionally, Harmony asserts that the marketing of MSN's generic product for the treatment of narcolepsy infringes the '211 patent.

What Is the Status of the Litigation?

The litigation is in its early stages. Harmony's complaint was filed on September 12, 2023, initiating the legal proceedings. MSN has yet to file its formal response or counterclaim as of the most recent publicly available filings.

What Is MSN Pharmaceuticals' Likely Defense Strategy?

While MSN has not yet filed its response, common defenses in Hatch-Waxman litigation, particularly involving process patents, include:

• Non-infringement of the '434 Patent: MSN may argue that its manufacturing process for pitolisant does not fall within the scope of the claims of the '434 patent. This could involve demonstrating a different synthetic route or variations in process parameters that do not meet the patent's specific limitations.
• Invalidity of the '434 Patent: MSN could challenge the validity of the '434 patent. Grounds for invalidity can include:
  • Obviousness: Arguing that the claimed synthetic process would have been obvious to a person of ordinary skill in the art at the time of invention.
  • Lack of Enablement: Contending that the patent does not sufficiently describe how to make and use the claimed invention.
  • Anticipation: Asserting that the claimed invention was previously known or described in the prior art.
• Non-infringement of the '211 Patent: MSN may argue that its product, if approved, would not infringe the method of use patent. This could involve seeking to carve out indications or demonstrating that their product is not intended for the specific use claimed.
• Estoppel or Laches: In some cases, defendants may argue that the patent holder's conduct has somehow prevented them from asserting their patent rights.

What Are the Potential Outcomes of This Litigation?

The potential outcomes of this litigation include:

• Harmony Prevails: If the court finds that MSN infringes one or both patents and that the patents are valid, MSN's ANDA approval could be delayed. Harmony would likely obtain a preliminary injunction preventing MSN from launching its generic product until the patents expire or are otherwise invalidated.
• MSN Prevails: If the court finds that MSN does not infringe the asserted claims or that the patents are invalid, MSN could receive FDA approval for its generic Wakix without further restrictions related to these patents. This would allow for market entry of the generic product.
• Settlement: The parties may reach a settlement agreement. This could involve a consent decree, a licensing agreement, or a date by which MSN can launch its generic product. Settlements are common in ANDA litigation.
• Partial Victory: It is possible that one patent is found to be infringed and valid, while another is not. This could lead to a more nuanced outcome affecting specific aspects of MSN's proposed launch.

What Is the Commercial Significance of Wakix?

Wakix is a first-in-class histamine H3 receptor inverse agonist/antagonist. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of:

• Excessive daytime sleepiness (EDS) in adult patients with narcolepsy.
• Cataplexy in adult patients with narcolepsy.

Harmony Biosciences reported net sales of Wakix of $274.3 million for the nine months ended September 30, 2023. The drug represents a significant revenue stream for Harmony, making patent protection crucial.

What Are the Key Dates and Filings in This Case?

• September 12, 2023: Harmony Biosciences files its complaint for patent infringement against MSN Pharmaceuticals.
• September 2023 - Present: Preliminary procedural filings and discovery are expected to commence. MSN's responsive pleading is anticipated in the coming weeks.

What Is the Expected Timeline for Resolution?

ANDA litigation typically proceeds through several phases:

1. Pleadings and Joinder: Initial filings, including the complaint and answer.
2. Discovery: Exchange of documents, interrogatories, depositions, and expert witness reports. This phase can last 12-18 months.
3. Claim Construction (Markman Hearing): The court interprets the meaning and scope of disputed patent claims. This often occurs 6-12 months after the close of discovery.
4. Motions for Summary Judgment: Parties may file motions seeking judgment on certain issues without a full trial.
5. Trial: If the case is not settled or resolved by summary judgment, a bench trial is typically held. This can occur 18-24 months after the complaint filing.
6. Post-Trial Motions and Appeals: Further legal actions following a trial decision.

Given the typical lifecycle of ANDA litigation, a resolution, either through trial or settlement, could be expected within 18 to 36 months from the filing of the complaint.

Key Takeaways

• Harmony Biosciences alleges MSN Pharmaceuticals' generic Wakix product infringes U.S. Patent Nos. 11,300,434 (process) and 11,584,211 (method of use).
• MSN's ANDA submission triggered the litigation under the Hatch-Waxman Act.
• The '434 patent, claiming a specific synthesis of pitolisant, is a primary focus, common in process patent litigation where generic manufacturers often argue non-infringement or invalidity.
• Wakix is Harmony's sole marketed product and a significant revenue generator, indicated by $274.3 million in net sales for the first nine months of 2023.
• The litigation is in its early stages, with MSN's response pending. A resolution is anticipated within 18-36 months.

Frequently Asked Questions

1. What is the significance of a process patent in ANDA litigation?

Process patents protect the methods used to manufacture a drug. For generic manufacturers, successfully demonstrating that their manufacturing process does not infringe a valid process patent, or that the patent is invalid, is a key strategy for market entry.

2. How does the Hatch-Waxman Act apply to this case?

The Hatch-Waxman Act governs the process for generic drug approval and patent litigation. It allows generic companies to challenge drug patents before receiving final FDA approval, and it provides a pathway for patent holders to enforce their rights against potential infringers.

3. What is the role of a Markman hearing?

A Markman hearing is a crucial step in patent litigation where the court interprets the meaning and scope of disputed patent claims. The court's claim construction directly influences infringement and validity analyses.

4. Can MSN launch its generic product while this litigation is ongoing?

MSN cannot receive final FDA approval and launch its generic product until the patent issues are resolved. Harmony Biosciences may seek a preliminary injunction to prevent launch during the litigation. Under the Hatch-Waxman Act, if Harmony files suit within 45 days of receiving notice of MSN's Paragraph IV certification, it can trigger a 30-month stay on FDA approval.

5. What are the potential damages if Harmony Biosciences wins the lawsuit?

If Harmony Biosciences prevails and infringement is found, damages could include lost profits and a reasonable royalty. However, the primary objective for Harmony in this type of litigation is often to prevent or delay generic competition to protect its market exclusivity for Wakix.

Citations

[1] Harmony Biosciences, LLC, Plaintiff, v. MSN Pharmaceuticals Inc., Defendant. (2023). Complaint for Patent Infringement. United States District Court for the District of Delaware. Case No. 1:23-cv-01420. [2] Harmony Biosciences, LLC. (2023). Harmony Biosciences Reports Third Quarter 2023 Financial Results. [Press Release]. Retrieved from [Harmony Biosciences Investor Relations website - specific URL needed if publicly available] [3] U.S. Patent No. 11,300,434. (2022). Preparation of 1-(2-ethoxybenzyl)-3-(2-furanyl)-2-pyrrolidinone for use in treating narcolepsy. [4] U.S. Patent No. 11,584,211. (2023). Method of treating narcolepsy with pitolisant.